Experimental Basis of Bone Marrow Purging with Chemical and Photodynamic Agents

  • A. Porcellini
  • A. Manna
  • M. T. Marchetti-Rossi
  • F. Centis
  • N. Talevi
  • G. Sparaventi
  • C. Pazzaglia
  • A. Bocconcelli
  • M. Palazzi
Part of the Experimental Hematology Today—1987 book series (HEMATOLOGY, volume 1987)


The major stumbling-block in ABMT is the high relapse rate compared to that observed in both allogeneic and syngeneic marrow transplant (1). This is possibly due to occult leukemic cells contaminating the remission marrow. Although the efficacy of the ex-vivo purging procedure has yet to be definitely established in clinical practice, there are indications that cleansing the marrow is associated with improved survival in some cases (1, 2). To meet the obvious need for methods capable of eliminating these cells from autologous marrow, several techniques have been investigated (3–7).


Pluripotential Stem Cell Autologous Bone Marrow Transplantation Clonogenic Cell Acute Myelogenous Leukemic Cell Limit Dilution Assay 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gorin NC, Aegerter P (1987) Autologous bone marrow transplantation for acute leukemia in remission: 4th EBMT survey. Bone Marrow Transplantation 2 (suppl. 1):320–21Google Scholar
  2. 2.
    Yeager AM, Kaizer H, Santos GW, Sarai R, Colvin OM, Stuart RK, Braine HG, Burke PJ, Ambinder RF, Burns WH, Fuller DJ, Davis JM, Karp JE, Stradford May W, Rowley SD, Sensenbrenner LL, Vogelsang GB, Wingard JR (1986) Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Eng J Med 315:141–47CrossRefGoogle Scholar
  3. 3.
    Bast RC, De Fabritiis P, Lipton J, Gelber R, Maver C, Nadler L, Sallan S, Ritz J (1985) Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res 45: 499–506PubMedGoogle Scholar
  4. 4.
    Leonard JE, Taetle R, To D, Rhyner K(1985) Preclinical studies on the use of selective antibodyricin conjugates in autologous bone marrow transplantation. Blood 65:1149–53PubMedGoogle Scholar
  5. 5.
    Uckun FM, Ramakrishnan S, Houston LL (1985) Increased efficiency in selective elimination of leukemia cells by a combination of a stable derivative of cyclophosphamide and a human B-cell- specific immunotoxin containing pokeweed antiviral protein. Canc Res 45:69–75Google Scholar
  6. 6.
    Berenson RJ, Bensinger WI, Kalamasz D, Martin P (1986) Elimination of Daudi lymphoblasts from human bone marrow using avidinbiotin immune adsorption. Blood 67:509–15PubMedGoogle Scholar
  7. 7.
    Uckun FM, Gajl-Peczalska K, Meyers DE, Ramsay NC, Kersey JH, Colvin M, Vallera DA (1987) Marrow purging in autologous bone marrow transplantation for T-lineage acute lymphoblastic leukemia: Efficacy of ex-vivo treatment with immunotoxins and 4- hydroperoxycyclophosphamide against fresh leukemic marrow progenitor cells. Blood 69:361–65PubMedGoogle Scholar
  8. 8.
    Sharkis SJ, Santos GW, Colvin M (1980) Elimination of acute myelogenous leukemic cells from marrow and tumor suspensions in the rat with 4-hydroperoxycyclophosphamide. Blood 55:521–23PubMedGoogle Scholar
  9. 9.
    Sarpel SC, Epstein RB (1979) Chemoseparation of cell populations in dogs by activated cyclophosphamide. Blood 54:230a (abstr.)Google Scholar
  10. 10.
    Porcellini A, Manna A, Talevi N, Sparaventi G, Marchetti-Rossi MT, Baronciani D, De Biagi M (1984) Effect of two cyclophos — phamide derivatives on hemopoietic progenitor cells and pluripotential stem cells. Exp Hematol 12:863–66PubMedGoogle Scholar
  11. 11.
    Sieber F, Meagher RC, Spivak JL (1981) Differential sensitivity of mouse hematopoietic stem cells to merocyanine-540. Differentiation 19:65–69PubMedCrossRefGoogle Scholar
  12. 12.
    Meagher RC, Sieber F, Spivak JL (1983) Susceptibility to merocyanine-540-mediated photosensitization: a differentiation marker on murine hematopoietic progenitor cells. J Cell Physiol 116:118–24PubMedCrossRefGoogle Scholar
  13. 13.
    Sieber F, Spivak JL, Sutcliffe AM (1984) Selective killing of leukemic cells by merocyanine-540-mediated photosensitization. Proc Natl Acad Sci USA 81:7584–87PubMedCrossRefGoogle Scholar
  14. 14.
    Porcellini A, Talevi N, Marchetti-Rossi MT, Manna A, Sparaventi G, Palazzi M (1985) Selective elimination of leukemic cells from marrow cell suspensions by mafosfamide (AZ) or merocyanine-540 (MC). Blood 66(suppl. 1): 270 (abstr.)Google Scholar
  15. 15.
    Magli MC, Iscove NN, Odartchenko N (1982) Transient nature of early haematopoietic spleen colonies. Nature 295:527–29PubMedCrossRefGoogle Scholar
  16. 16.
    Moriyama Y, Narita M, Sato K, Urushiyama M, Koyama S, Hirosawa H, Kishi K, Takai K, Takahashi M, Shibata A (1986) Application of hyperthermia to the treatment of human acute leukemia: purging human leukemic progenitor cells by heat. Blood 67:802–04PubMedGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1988

Authors and Affiliations

  • A. Porcellini
  • A. Manna
  • M. T. Marchetti-Rossi
  • F. Centis
  • N. Talevi
  • G. Sparaventi
  • C. Pazzaglia
  • A. Bocconcelli
  • M. Palazzi

There are no affiliations available

Personalised recommendations